Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
29.44
+0.17 (0.58%)
At close: Apr 28, 2026, 4:00 PM EDT
30.00
+0.56 (1.90%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Catalyst Pharmaceuticals stock has a target of 35, which predicts an increase of 18.89% from the current stock price of 29.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Catalyst Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $33 → $35 | Strong Buy | Maintains | $33 → $35 | +18.89% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +12.09% | Nov 7, 2025 |
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +8.70% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +18.89% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $33 | Buy | Reiterates | $33 | +12.09% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
643.19M
from 588.99M
Increased by 9.20%
Revenue Next Year
710.80M
from 643.19M
Increased by 10.51%
EPS This Year
1.92
from 1.68
Increased by 14.14%
EPS Next Year
2.20
from 1.92
Increased by 14.57%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 671.7M | 764.3M | ||||||
| Avg | 643.2M | 710.8M | ||||||
| Low | 608.6M | 620.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.0% | 18.8% | ||||||
| Avg | 9.2% | 10.5% | ||||||
| Low | 3.3% | -3.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.14 | 2.75 | |||
| Avg | 1.92 | 2.20 | |||
| Low | 1.71 | 1.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.5% | 43.5% | |||
| Avg | 14.1% | 14.6% | |||
| Low | 1.5% | -11.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.